HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.

33 Clinical Trials
Multiple Myeloma NA Active
nct/study# NA / DAH-C-21-USA-003

A Retrospective Chart Review Of Daratumumab In Actively Diagnosed Multiple

Learn More
Multiple Myeloma Phase I/II Active
nct/study# NA / LAVA-051

A Phase 1 And 2a Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity And Antitumor Activity Of LAVA-051 In Patients With Relapsed Or Refractory CD1d-Positive Chronic Lymphocytic Leukemia, Multiple Myeloma Or Acute Myeloid Leukemia

Learn More
Multiple Myeloma Phase I Active
nct/study# NA / NL-201-MM

Phase 1 IV-Infusion Study Of Our Investigational Drug, NL-201

Learn More
Multiple Myeloma Phase 1/2 Active
nct/study# NA / CP-NEXI-002-01

A Phase 1 / 2 Study To Evaluate The Safety And Tolerability Of Adoptively Transferred Autologous T Cells In Patients With Relapsed Refractory Multiple Myeloma

Learn More
Multiple Myeloma NA Active
nct/study# NA / 2021-0704

Safety Of Switching From Intravenous Daratumumab To Subcutaneous Daratumumab In Patients With Multiple Myeloma

Learn More
Multiple Myeloma Phase I/II Accepting Patients
nct/study# NCT03288493 / P-BCMA-101-001

Open-Label, Multicenter, Phase 1 Study To Assess The Safety Of P BCMA-101 In Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed By A Phase 2 Assessment Of Response And Safety (PRIME)

Learn More

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.